

Certificate of Analysis

Fms, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-551, 14-551-K, 14-551M

Parent Lot # 1625861

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, human FMS, amino acids 538–end, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 94.1% by SDS-PAGE and Coomassie blue staining. MW = 50.2kDa.

Specific Activity (Parent lot# 1625861): this lot showed a minimum activity of 317U/mg, where one unit of FMS activity is defined as 1nmol phosphate incorporated into 250µM (KKKSPGEYVNIEFG) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.282mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 14–64ng of this lot of enzyme phosphorylated 250µM (KKKSPGEYVNIEFG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed product identity as FMS with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS pH 7.0, 1mM EDTA.
2. **(KKKSPGEYVNIEFG):** Use at a final assay concentration of 250 μ M. Make a 2.5mM stock. Use 2.5 μ l per assay point.
3. **FMS, active:** Dilute with 20mM MOPS pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 14–64ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **(KKKSPGEYVNIEFG)**.
3. Add **2.5 μ l (14–64ng) FMS, active**.
4. Add 5 μ l dH₂O.
5. Add 10 μ l of diluted [γ -³³P] ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

FMS Sequence Information

<u>Protein</u>	Human FMS
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	Y10 of the recombinant protein is equivalent to Y538 of human FMS
<u>Accession number</u>	GenBank U63963

Recombinant FMS amino acid sequence:

```

1 MHHHHHHEFY KYKQKPKYQV RWKIIESYEG NSYTFIDPTQ LPYNEKWEFP RNNLQFGKTL
61 GAGAFGKVV E ATAFGLGKED AVLKVAVKML KSTAHADEKE ALMSELKIMS HLGQHENIVN
121 LLGACTHGGP VLVITEYCCY GDLLNFLRRK AEAMLGPSLS PGQDPEGGVD YKNIHLEKKY
181 VRRDSGFSSQ GVDTYVEMRP VSTSSNDSFS EQDLDKEDGR PLELRDLLHF SSQVAQGMAF
241 LASKNCIHRD VAARNVLLTN GHVAKIGDFG LARDIMNDSN YIVKGNARLP VKWMAPESIF
301 DCVYTVQSDV WSYGILLWEI FSLGLNPYPG ILVNSKFYKL VKDGYQMAQP AFAPKNIYSI
361 MQACWALEPT HRPTFQQICS FLQEQAQEDR RERDYTNLPS SSRSGSGSS SSELEEESSS
421 EHLTCCEQGD IAQPLLQPNN YQFC
  
```

Recombinant FMS nucleotide sequence:

```

1 atgcatcatc accatcacca tgaattctac aagtataagc agaagcccaa gtaccaggtc
61 cgctggaaga tcatcgagag ctatgagggc aacagttata ctttcatcga ccccacgcag
121 ctgccttaca acgagaagtg ggagttcccc cggacaacc tgcagtttgg taagaccctc
181 ggagctggag ctttgggaa ggtggtggag gccacggcct ttggtctggg caaggaggat
241 gctgtcctga agtggtgctg gaagatgctg aagtccacgg cccatgctga tgagaaggag
301 gccctcatgt ccgagctgaa gatcatgagc cacctgggcc agcacgagaa catcgtcaac
361 cttctgggag cctgtacca tggaggccct gtactggtca tcacggagta ctggtgctat
421 ggcgacctgc tcaactttct gcgaaggaag gctgaggcca tgctgggacc cagcctgagc
481 cccggccagg accccgaggg aggcgtcgac tataagaaca tccacctcga gaagaaatat
541 gtccgcaggg acagtggcct ctccagccag ggtgtggaca cctatgtgga gatgaggcct
601 gtctccactt cttcaaatga ctcttctct gagcaagacc tggacaagga ggatggacgg
661 cccctggagc tccgggacct gcttcaactt tccagccaag tagcccaggg catggccttc
721 ctgccttcca agaattgcat ccaccgggac gtggcagcgc gtaacgtgct gttgaccaat
781 ggtcatgtgg ccaagattgg ggacttcggg ctggctaggg acatcatgaa tgactccaac
841 tacattgtca agggcaatgc ccgctgctt gtgaagtgga tggccccaga gagcatcttt
901 gactgtgtct acacggttca gagcgacgct tggctctatg gcatcctcct ctgggagatc
961 ttctcacttg ggctgaatcc ctaccctggc atcctggtga acagcaagtt ctataaactg
1021 gtgaaggatg gataccaaat ggcccagcct gcatttgccc caaagaatat atacagcatc
1081 atgcaggcct gctgggcctt ggagcccacc cacagacca cttccagca gatctgctcc
1141 ttccttcagg agcaggccca agaggacagg agagagcggg actataccaa tctgccgagc
1201 agcagcagaa gcggtggcag cggcagcagc agcagtgagc tggaggagga gagctctagt
1261 gagcacctga cctgctgcca gcaaggggat atcgcccagc cttgctgca gcccaacaac
1321 tatcagttct gctga
  
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.